Search PubMed⌕ Search

Biomedical subjects

M Shepherd

Publications and source records attributed to M Shepherd.

At least 199 records · Page 11Linked to original sources
PubMed1965

Clinically important examples of drug interaction. Psychotropic drugs (1). Interaction between centrally acting drugs in man: some general considerations.

As a biological phenomenon the interaction between drugs may be viewed in ;explanatory' or ;empirical' terms. In clinical psychopharmacology the former is rarely possible: two examples are cited, one concerning amphetamine and reserpine, the other desmethyl-imipramine and tetrabenazine. Among centrally acting substances, empirical studies of the interaction between alcohol and the barbiturates have been pursued intensively by several methods in clinic and laboratory. Both general considerations and recent work on the effects of amphetamine-barbiturate combinations suggest caution in the medical use of mixtures of psychotropic drugs. Adverse reactions caused by interaction between psychotropic drugs and other substances have still to be studied systematically as a potential hazard.

Amphetamine↗
PubMedDate not supplied

Implementing the Safe Medical Devices Act in a hospital.

Implementation of the Safe Medical Devices Act (SMDA) by a "medical device user facility" requires the introduction of new responsibilities, processes, and accountabilities. The complexity of a program will vary with the number of devices included, as well as the medical activities of the particular facility. The implementation of the SMDA is described in a 145-bed, acute care, county hospital, along with some of the practical problems and solutions associated with its implementation. Both the event reportability section and the tracking section of SMDA have been implemented. The greatest difficulty in the event reportability section lies in the ambiguous definitions that determine event reportability. This ambiguity may be clarified when the final regulations are published. In respect to device tracking, questions remain unanswered that relate to the manufacturer-facility interface and disposition of explanted devices.

California↗